HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

triflusal

inhibits platelet aggregation similarly to aspirin; structure
Also Known As:
2-acetoxy-4-trifluoromethylbenzoic acid; Disgren; 2- (acetyloxy)-4-(trifluoromethyl)benzoic acid
Networked: 88 relevant articles (10 outcomes, 28 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Cechetto, David F: 4 articles (05/2018 - 08/2005)
2. Alvarez-Sabín, José: 3 articles (01/2014 - 04/2003)
3. Cheng, Guanliang: 3 articles (12/2010 - 08/2005)
4. Fuertes Ferre, Georgina: 2 articles (01/2021 - 07/2018)
5. Ahn, Seong Hwan: 2 articles (09/2017 - 01/2016)
6. Han, Sang Won: 2 articles (09/2017 - 01/2016)
7. Kim, Yong-Jae: 2 articles (09/2017 - 01/2016)
8. Kim, Youn Nam: 2 articles (09/2017 - 01/2016)
9. Lee, Kyung-Yul: 2 articles (09/2017 - 01/2016)
10. Oh, Seung-Hun: 2 articles (09/2017 - 01/2016)

Related Diseases

1. Atrial Fibrillation
2. Stroke (Strokes)
3. Ischemic Stroke
4. Cerebral Infarction
5. Body Weight (Weight, Body)
06/01/1990 - "The study of the prevention of platelet thrombi formation on these materials was carried out in 6 groups of 8 animals: group 1 (control), group 2 (5 mg/kg body weight/day acetylsalicylic acid), group 3 (20 mg/kg body weight/day acetylsalicylic acid), group 4 (15 mg/kg body wt/day triflusal plus 5 mg/kg body wt/day dipyridamole), group 5 (15 mg/kg body wt/day triflusal) and group 6 (5 mg/kg body wt/day acetylsalicylic acid plus 5 mg/kg body wt/day dipyridamole). "
10/01/1989 - "Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: group I, control; group II, 5 mg/kg body weight/day acetylsalicylic acid; group III, 20 mg/kg body weight/day acetylsalicylic acid; group IV, 15 mg/kg body weight/day triflusal + 5 mg/kg body weight/day dipyridamole; group V, 15 mg/kg body weight/day triflusal; and group VI, 5 mg/kg body weight/day acetylsalicylic acid + 5 mg/kg body weight/day dipyridamole. "
05/01/1989 - "Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: Group I, control; Group II, 5 mg/kg body weight/day acetylsalicylic acid; Group III, 20 mg/kg body wt/day acetylsalicylic acid; Group IV, 15 mg/kg body wt/day triflusal + 5 mg/kg body wt/day dipyridamole; Group V, 15 mg/kg body wt/day triflusal; and Group VI, 5 mg/kg body wt/day acetylsalicylic acid + 5 mg/kg body wt/day dipyridamole. "
11/01/2009 - "First, we prospectively tested platelet function with a rapid platelet function analyzer (VerifyNow-Aspirin) in patients with stable angina (male, age, 61.6 +/- 8.3, body weight, 69.3 +/- 11.2 kg) who maintained dual (aspirin 100 mg and clopidogrel 75 mg per day, n = 23) or triple (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day, n = 23) therapy for more than one month. "
04/01/2006 - "Assessment of the effects of triflusal in pressure overload-induced cardiac hypertrophy by aortic banding resulted in a significant reduction in the ratio of heart weight to body weight and in a reduction of the mRNA levels of the cardiac hypertrophy markers ANF and alpha-actinin compared with untreated banded rats. "

Related Drugs and Biologics

1. Aspirin (Acetylsalicylic Acid)
2. Dipyridamole (Persantine)
3. Clopidogrel (Plavix)
4. Ticlopidine (Ticlid)
5. Platelet Aggregation Inhibitors (Antiplatelet Drugs)
6. 4-trifluoromethylsalicylic acid (HTB)
7. indobufen
8. Anticoagulants
9. Cyclooxygenase 2 (Cyclooxygenase-2)
10. Acids

Related Therapies and Procedures

1. Therapeutics
2. Secondary Prevention
3. Bioprosthesis
4. Stents
5. Drug-Eluting Stents